Skip to content

US · MBOT · MEDICAL - INSTRUMENTS & SUPPLIES

Microbot Medical Inc. (MBOT) intrinsic value and stock valuation

$0.68as of 2026-11-21 · Mkt cap 84.31M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Microbot Medical Inc. DCF and intrinsic value

InvestorsCraft values MBOT with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from MBOT’s statements →

Microbot Medical Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Instruments & Supplies Hingham, MA 02043 microbotmedical.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$0.00
20112025
Net income
-$-13.14M
20112025
Free cash flow
-$-13.11M
20112025
Total equity
$77.6M+26.1% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-14.74M-$-11.62M-$-9.86M-$-13.28M-$-11.36M
Net income-$-13.14M-$-11.44M-$-10.74M-$-13.17M-$-11.31M
EPSd-$-286.96K-$-731.46K-$-1.05M-$-1.81M-$-1.59M
Operating cash flow-$-13.05M-$-8.83M-$-8.53M-$-11.55M-$-9.35M
Capital expenditure-$-60K-$-30K-$-30K-$-80K-$-70K
Free cash flow-$-13.11M-$-8.85M-$-8.57M-$-11.63M-$-9.42M
Total assets$81.5M$6.03M$8.33M$9.54M$16.8M
Total debt$860K$110K$230K$460K$680K
Net debt-$-3.05M-$-3M-$-2.24M-$-2.06M-$-12.81M
Total equity$77.6M$3.53M$4.5M$7.29M$14.4M
Cash and short-term investments$78.6M$5.47M$6.38M$8.28M$15.5M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$90K$110K$0.00$0.00
Gross profit$0.00-$-90K-$-110K$0.00$0.00
Research and development expenses$6.28M$6.63M$5.72M$7.74M$6.15M
Selling, general and administrative expenses$8.25M$5M$4.13M$5.58M$5.41M
Other expenses$210K-$-90K-$-110K-$-40K-$-210K
Operating expenses$14.7M$11.5M$9.75M$13.3M$11.4M
Cost and expenses$14.7M$11.6M$9.86M$13.3M$11.4M
Interest income$1.28M$180K$230K$50K$40K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$50K$90K$110K$100K$80K
Ebitda-$-13.1M-$-11.35M-$-10.63M-$-13.34M-$-11.24M
Operating income-$-14.74M-$-11.62M-$-9.86M-$-13.28M-$-11.36M
Total other income/expenses, net$1.6M$180K-$-890K$110K$40K
Income before tax-$-13.14M-$-11.44M-$-10.74M-$-13.17M-$-11.31M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-13.14M-$-11.44M-$-10.74M-$-13.17M-$-11.31M
Weighted average shares outstanding$45.8M$15.6M$10.2M$7.26M$7.11M
Weighted average diluted shares outstanding$45.8M$15.6M$10.2M$7.26M$7.11M
Balance sheet
20252024202320222021
Cash and short-term investments$78.6M$5.47M$6.38M$8.28M$15.5M
Net receivables$240K$300K$1.49M$100K$170K
Inventory$580K$0.00$0.00$0.00$0.00
Total current assets$79.8M$5.82M$7.92M$8.81M$15.9M
Property, plant and equipment, net$930K$210K$410K$720K$890K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$1.72M$210K$410K$720K$890K
Total assets$81.5M$6.03M$8.33M$9.54M$16.8M
Accounts payable$510K$170K$360K$120K$280K
Short-term debt$300K$70K$190K$280K$280K
Deferred revenue$90K$0.00$0.00$0.00$0.00
Total current liabilities$3.42M$2.46M$3.79M$2.07M$1.98M
Long-term debt$570K$40K$40K$180K$400K
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$570K$40K$40K$180K$400K
Capital lease obligations$860K$110K$230K$180K$680K
Total liabilities$3.99M$2.5M$3.83M$2.25M$2.39M
Common stock$670K$200K$120K$80K$70K
Retained earnings-$-104.09M-$-90.94M-$-79.5M-$-68.76M-$-55.59M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00$0.00$0.00
Total equity$77.6M$3.53M$4.5M$7.29M$14.4M
Total investments$74.7M$2.36M$3.92M$5.76M$2M
Total debt$860K$110K$230K$460K$680K
Net debt-$-3.05M-$-3M-$-2.24M-$-2.06M-$-12.81M
Cash flow statement
20252024202320222021
Net income-$-13.14M-$-11.44M-$-10.74M-$-13.17M-$-11.31M
Depreciation and amortization$50K$90K$110K$100K$80K
Stock-based compensation$1.06M$1.35M$1.39M$1.75M$1.39M
Change in working capital-$-1.5M$940K-$-10K-$-230K$500K
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory-$-580K$0.00$0.00$0.00$0.00
Accounts payable$0.00$0.00$0.00$0.00$0.00
Net cash provided by operating activities-$-13.05M-$-8.83M-$-8.53M-$-11.55M-$-9.35M
Investments in property, plant and equipment-$-60K-$-30K-$-30K-$-80K-$-70K
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-72.38M$1.54M$1.97M-$-3.84M$3.2M
Common stock issued$86.2M$7.94M$6.56M$4.32M$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$86.2M$7.94M$6.56M$4.32M$0.00
Net change in cash$810K$650K-$0.00-$-11.06M-$-6.15M
Cash at end of period$3.97M$3.16M$2.52M$2.52M$13.6M
Operating cash flow-$-13.05M-$-8.83M-$-8.53M-$-11.55M-$-9.35M
Capital expenditure-$-60K-$-30K-$-30K-$-80K-$-70K
Free cash flow-$-13.11M-$-8.85M-$-8.57M-$-11.63M-$-9.42M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Microbot Medical Inc.

        Microbot Medical Inc. operates as a pre-clinical stage medical device company, concentrating its efforts on the research, design, and development of robotic instruments for endoluminal surgery, specifically targeting the field of minimally invasive procedures. Leveraging its proprietary micro-robotic technologies, which include ViRob, TipCAT, CardioSert, and Liberty, the company is actively developing several key products. These include a Self-Cleaning Shunt intended for the treatment of hydrocephalus and normal pressure hydrocephalus, as well as a single-use robotic system designed for various endovascular interventional applications. Additionally, Microbot Medical maintains a robust, multi-generational product pipeline. Its global intellectual property portfolio is substantial, encompassing 42 granted or allowed patents and an additional 23 patent applications currently under review. The company also benefits from a strategic collaboration agreement with Stryker Corporation, focusing on joint technology development. Established in 2010, Microbot Medical Inc. is headquartered in Hingham, Massachusetts.

        CEO
        Harel Gadot
        Employees
        43
        Beta
        1.04

        Explore

        Frequently asked questions

        What is the intrinsic value of Microbot Medical Inc. (MBOT)?

        InvestorsCraft does not currently publish an intrinsic value for MBOT. How the IC value is calculated.

        Is MBOT undervalued?

        InvestorsCraft does not publish an undervaluation signal for MBOT at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.